Long-Term Safety and Real-World Effectiveness of Fingolimod in Relapsing Multiple Sclerosis

Patient Related Outcome Measures
doi 10.2147/prom.s122401
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Real-World Effectiveness and Safety of Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients: An Observational Study

PLoS ONE
Multidisciplinary
2017English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life

Patient Related Outcome Measures
2014English

Long-Term Effects of Fingolimod in Multiple Sclerosis: The Randomized FREEDOMS Extension Trial

Neurology
Neurology
2015English

Fingolimod and CSF Neurofilament Light Chain Levels in Relapsing-Remitting Multiple Sclerosis

Neurology
Neurology
2015English

Alemtuzumab in the Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis: An Update on the Clinical Trial Evidence and Data From the Real World

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2017English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Design of a Non-Interventional Post-Marketing Study to Assess the Long-Term Safety and Effectiveness of Ocrelizumab in German Real World Multiple Sclerosis Cohorts – The CONFIDENCE Study Protocol

BMC Neurology
MedicineNeurology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy